SHOULD we now embark on daring skin-to-skin missions? I am pretty sure this is what some people were asking when they heard that a long-acting HIV prevention drug is now available in Zambia. In a recent act of global health generosity, the United States Government made a remarkable contribution to Zambia’s well-being; 14,850 vials of the innovative injectable PrEP, famously known as Cabotegravir Long Acting (CAB-LA). This momentous donation has not only positioned Zambia at the forefront of African nations but has also marked a historic stride in the global fight against HIV. I caught up with Ministry of Health Director of Infectious Diseases Professor Lloyd Mulenga who explains in detail what Cabotegravir is and why not everyone can take...

This premium content is for paid ePaper subscribers.
Subscribe
Already a member? Log in here